Diagnosing Myeloproliferative Neoplasms

There are tests available that examine the blood and bone marrow to detect and diagnose chronic myeloproliferative neoplasms.

The Penn Medicine hematopathology service is a national leader in the diagnosis of neoplastic and reactive hematologic disorders, with broad expertise in myeloproliferative neoplasms.

Working closely with the clinical team, Penn hematopathologists provide integrative, state-of-the art analysis using histology and a wide array of ancillary techniques, including:

  • Flow cytometry
  • Immunohistochemistry
  • Cytogenetics
  • FISH, and
  • The latest molecular studies (ranging from single gene assays to next generation sequencing) to ensure the most accurate and precise diagnosis for every patient.

Getting A Second Opinion from Penn

If you were diagnosed at another health care center, and are coming to the Abramson Cancer Center for treatment or a second opinion, repeat diagnostic tests may be necessary.

Other things we may request in advance of your second opinion visit include:

  • Pathology slides
  • Health records
  • A list of dates and facts about your past treatments, personal health history, or any other facts and dates relevant to your current diagnosis

Perhaps most importantly, however, come to your visit with a list of as many questions as possible. Sometimes, it can be difficult to think of, or remember everything, during a visit. A list of questions prepared in advance will ensure you get the information you are looking for.

If you forget a question, or have more questions after your visit, log on to www.myPennMedicine.org. Here, you can communicate with us via a secure network even if it's after your appointment.

Finally, plan to have a friend, family member or support person come with you to your appointment. He or she can help take down information, recall the conversation and be of general support throughout the process.

Diagnostic Tools for MPN

Abramson Cancer Center utilizes a variety of leading edge diagnostic tools and tests to diagnose myeloproliferative neoplasms.